Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abraxane plus Bevacizumab in Recurrent Ovarian Cancer
NCT01821859Phase 2Terminated
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Jan 2010
- Primary completion
- Nov 2011
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nab-paclitaxel in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by OHSU Knight Cancer Institute. Started Jan 2010; status: terminated.
02
Drugs
nab-paclitaxel
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT01821859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01821859.